Compare XLO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | IPSC |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 49.8M |
| IPO Year | 2021 | 2021 |
| Metric | XLO | IPSC |
|---|---|---|
| Price | $0.65 | $0.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.00 | ★ $3.00 |
| AVG Volume (30 Days) | 528.0K | ★ 934.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $31,804,000.00 | ★ $113,337,000.00 |
| Revenue This Year | $589.60 | $1,590.09 |
| Revenue Next Year | $38.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 588.40 | ★ 4122.69 |
| 52 Week Low | $0.62 | $0.34 |
| 52 Week High | $1.70 | $1.38 |
| Indicator | XLO | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 56.92 |
| Support Level | $0.68 | $0.50 |
| Resistance Level | $0.73 | $0.62 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.24 | 64.59 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.